Bharat Parenterals has announced an Extraordinary General Meeting for October 23, 2026, to seek shareholder approval for raising Rs 138.99 crore through a preferential issue of 9,12,759 equity shares at Rs 1,522.85 each. The capital is primarily earmarked for subsidiary investments. Additionally, the company seeks to expand its loan and guarantee limits under Section 186 to support group-level financial flexibility.
Bharat Parenterals Announces Rs 139 Crore Preferential Allotment
Total capital infusion is set at Rs 138.99 crore through issuance of 9,12,759 shares.
The company plans to deploy Rs 135 crore of this for subsidiary investments.
Reader Takeaway: The capital injection strengthens balance sheet for expansion, though dilution for existing shareholders is expected.
What just happened
Bharat Parenterals Ltd has scheduled an Extraordinary General Meeting (EGM) for October 23, 2026. The board is seeking shareholder approval for a preferential allotment of equity shares to non-promoter institutional investors. Investors such as WhiteOak Capital schemes and Ashoka India Equity Investment Trust are among the proposed allottees. The issue price is fixed at Rs 1,522.85 per share, aligned with SEBI's floor price regulations.
Why this matters
This fundraise is a strategic move to boost the company’s liquidity. By allocating Rs 135 crore specifically for existing and future subsidiary investments, the company is signaling an aggressive push to scale its underlying business segments. The board also seeks to increase borrowing and guarantee limits by Rs 140 crore under Section 186 of the Companies Act, providing the management with greater operational agility.
What changes now
The company’s paid-up capital will increase upon the completion of this issue, diluting current holdings slightly. However, management has confirmed that this transaction will not result in any change in management control. The shares issued will be subject to statutory lock-in periods as mandated by SEBI ICDR regulations.
Risks to watch
Investors should monitor the efficiency of the capital deployment. While the company has a two-year window to utilize these funds, any delay in subsidiary project execution or failure to achieve anticipated returns could pressure future profitability. Furthermore, the enhanced power to provide corporate guarantees increases the company’s exposure to the financial performance of its subsidiaries.
What to track next
Shareholders should track the outcome of the e-voting process, which remains open from October 20 to October 22, 2026. Post-EGM, the key focus will be on the actual timeline for subsidiary project implementation and the company’s ability to maintain its margin profiles despite the equity dilution.